Sarepta Therapeutics, Inc. (SRPT) announced on Thursday that it has entered into agreements with investors to restructure ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The Asian Investor sees significant improvement in XPeng’s (XPEV) vehicle margin profile, leading to a more positive outlook on the stock. In contrast, Seeking Alpha analysts have made notable ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer talked about. A caller asked for Cramer’s outlook on the stock, and he commented: “Oh God. I was hoping it’s not Sarepta. I don ...

Sarepta Therapeutics obtained traditional FDA approval for ambulatory DMD patients and accelerated approval for non-ambulatory DMD patients with a confirmed mutation in the DMD gene on the 20th of ...

What To Know: Under privately negotiated exchange agreements, Sarepta will swap about $700 million in aggregate principal amount of its existing convertible notes for approximately $602 million in new ...

Fintel reports that on May 14, 2024, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Perform to Outperform. As of May 8, 2024, the average one-year price target ...

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT Provided by PR Newswire Jul 21, 2025, 8:15:00 AM ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the August 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...